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Six macaques, apparently uninfected, following low-dose exposure to the pathogenic SIVmac251 and SIVSME660 by the mucosal
route, were used in a pilot study to investigate whether infectability of ex vivo lymph nodes could predict resistance and/or
susceptibility to SIV infection in vivo. Of six macaques exposed to the less-pathogenic virus SIVMNE, four resisted viral
infection. Analysis of the susceptibility of the PBMC of these four animals before SIVMNE challenge indicated that all of them
were resistant to infection by the SIVBK28 isolate and, in three of them, this resistance was dependent on CD81 T cells. Blocks
of lymph nodes of these four macaques were resistant to SIVMNE infection ex vivo following SIVMNE viral challenge exposure.
However, the same blocks from the same animals were permissive to the more virulent SIV251(32H). Accordingly, three of these
macaques were readily infected following challenge exposure with SIV251(32H). Lymphoproliferative responses in blood or
lymph nodes, local C-C chemokine production in the lymph-node explants, and cytotoxic T-cell activity measured throughout
the study did not correlate with ex vivo resistance or susceptibility to in vivo infection. In conclusion, PBMC and lymph-node
resistance or susceptibility to infection ex vivo appeared to correlate with in vivo infectivity and, thus, these approaches
should be further tested for their predictive value for in vivo infection. © 2000 Academic Press
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SIV infection of rhesus macaques has been developed
as a model to study HIV disease. In the SIV macaque
model, particularly following mucosal exposure, low
doses of SIV may result in latent or occult infection and,
despite knowledge on the time and dose of exposure,
the assessment of the mechanism(s) underlying resis-
tance to viral infection has proven difficult (Clerici et al.,
1994b; Cranage et al., 1998; Dittmer et al., 1996; Lohman
et al., 1994; McChesney et al., 1998; Neildez et al., 1998;
Petry et al., 1997; Trivedi et al., 1994). In humans, where
exposure could only be inferred by risk behavior, the
natural or acquired correlates of resistance are also
unknown (Clerici et al., 1994a; Mazzoli et al., 1997; Pinto
et al., 1995; Shearer and Clerici, 1996). Recent evidence
in HIV-1-exposed (presumably uninfected) Gambian
women and uninfected infants born to HIV-1-infected
mothers suggests that virus-specific CD81 responses
may be associated with viral resistance (Cheynier et al.,
1 To whom correspondence and reprint requests should be ad-
ressed at National Institutes of Health, Basic Research Laboratory,
ational Cancer Institute, 41 Library Drive, Building 41, Room D804,
ethesda, MD 20892. Fax: (301) 402-0055. E-mail: veffa@helix.nih.gov.
3911992; De Maria et al., 1994; Rowland-Jones et al., 1993,
1995).
However, multiple mechanisms may underlie the re-
sistance of some individuals to HIV-1 (Fauci, 1996). Here
we have attempted to address the issue by studying a
cohort of six macaques previously exposed to low doses
of SIVmac251 (Miller et al., 1994) or SIVSME660 (Goldstein et
l., 1994) and studying immunological and virological
arameters in blood and tissues of these macaques
ollowing sequential exposure to SIV isolates that dif-
ered in their virulence. All the viral isolates in this study
ere genetically and immunologically related and were
ble to induce AIDS in macaques. However, their levels
f viral replication in vivo differed (Benson et al., 1998;
Benveniste et al., 1990; Cranage et al., 1992; Hu, 1994;
Miller et al., 1994). The six macaques used in this study
resisted a low dose of either SIV251 or SIVSME660 and
nalysis of the immune responses in the blood did not
ffer clues to the nature of this resistance. Thus, exper-
ments were designed to address whether the in vitro
usceptibility of the PBMC of these macaques to SIV
orrelated with resistance to a subsequent SIVMNE chal-
lenge exposure. In addition, we investigated whether the
resistance of the PBMC to SIV replication was depen-
dent on CD81 T cells to assess whether protection from
0042-6822/00 $35.00
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392 MARGOLIS ET AL.infection was innate or the result of adaptive immunity
following exposure to a low dose of virus. Finally, we
assessed whether the susceptibility or resistance of ma-
caques to a given viral strain correlated with the suscep-
tibility or resistance of their ex vivo lymph nodes. The
ymph nodes of the animals that resisted SIVMNE chal-
lenge exposure remained resistant to SIVMNE in vitro.
However, the same lymph nodes replicated the more
virulent SIV251(32H) and subsequent exposure of these ma-
caques to SIV251(32H) resulted in overt infection and dis-
ease progression.
RESULTS AND DISCUSSION
In an attempt to make full use of nonhuman primate
resources and investigate a possible novel approach to
predict resistance and susceptibility to SIV infection in
vivo, we used six macaques exposed to low doses (Buge
et al., 1997) of either SIV251 (Miller et al., 1994) or SIVSME660
(Goldstein et al., 1994). All macaques were apparently
ninfected, as judged by negative virus isolation, consis-
ently negative DNA PCR, and the absence of sustained
ymphoproliferative responses to gag, env, and nef in
both lymph nodes and PBMC (Table 1). Virus isolation
was consistently negative (eight subsequent attempts of
virus isolation from PBMC of these animals within 8
months postexposure), and the sensitivity of our isolation
assay was assessed by a limiting-dilution method using
total PBMC from SIV-infected animals and CEMX174 as a
target cell. With this assay, virus isolation is usually
positive with 450 PBMC and occasionally with as few as
50 PBMC cells. The DNA PCR assay was described
previously (Buge et al., 1997).
To investigate possible immune correlates and assess
indirect evidence of viral infection (McChesney et al.,
1998; Shearer and Clerici, 1996) we measured CD41
T-cell-proliferative responses against SIV peptides de-
rived from the gag, env, and nef proteins (Clerici et al.,
1994b) simultaneously in the blood and in the lymph-
T
Stimulation Index in Tissue and Blood
Animal
Lymph node
PHA conA Gag Env Nef F
290 NDb ND ND ND ND
291 ND ND ND ND ND
292 136 309 2 2 2
294 182 180 2 2 2
295 49 307 2 2 2
352 ND ND ND ND ND
a 2 5 negative animals had a stimulation index of less than 3; stim
Benson et al., 1998).
b ND 5 not determined.node cells of these animals. Albeit all animals’ PBMC eproliferated in response to phytohemagglutinin (PHA) or
concanavalin A (ConA), proliferative responses to env
and nef were transient and found in one out of three
independent measurements in the blood, but not in the
lymph nodes, of animals 292 and 294 (Table 1). The
remaining seven animals did not proliferate in response
to viral antigens. Thus, the lack of sustained proliferative
response in the blood as well as in lymphoid tissues
combined with the inability to detect virus suggests that
these animals may have cleared the low-dose infection
by the pathogenic SIV strains, rather than have an occult
infection (McChesney et al., 1998).
Since innate protective response mediated by the
CD81 T cells has been described as another correlate in
humans as well as macaques and since CD81 T-cell-
independent resistance of PBMC to viral infection has
been observed in vitro (Vanessa Hirsch, unpublished
data), the susceptibility of PBMC in the presence and in
the absence of CD81 T cells was studied. As demon-
strated in Table 2, some differences were observed in
the susceptibility of macaque PBMC to replicate SIVBK28;
animals 291, 292, 295, and 352 replicated SIVBK28 at a
lower level than animals 290 and 294 in the presence of
CD81 T cells. However, when CD81 T cells were re-
moved, viral replication was rescued at levels observed
in animals 290 and 294 only in animal 292, suggesting
that in this animal the in vitro resistance to viral replica-
tion was dependent on CD81 T cells. In animals 291 and
352, the in vitro resistance to SIVBK28 replication was
bserved also with a tenfold increase of virus input and
as partly mediated by CD81 T cells, since their re-
oval moderately increased viral replication. Thus, re-
uced susceptibility of PBMC to infection was observed
n vitro in four out of six animals and, in one of the four
nimals, the decreased susceptibility was clearly depen-
ent on CD81 T cells. Since all of these six animals
esisted the first low-dose challenge of highly virulent
IV strains, these data indicate that none of the param-
IVSME660- and SIV251-Exposed Animals
a
PBMC
PHA conA gag1 env2 nef 3 Flu Ag
42 189 2 2 2 2
20 112 2 2 2 2
29 151 2 28 3 2
20 87 2 8 5 2
88 190 2 2 2 2
62 188 2 2 2 2
index was derived from the IL-2 production as previously describedABLE 1
of the S
lu Ag
ND
ND
2
2
2
ND
ulationters studied correlated tightly with in vivo resistance.
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393LYMPH-NODE SUSCEPTIBILITY TO SIV INFECTIONNext we tested whether these animals were suscep-
tible to the less-virulent SIVMNE strain. Since the SIVMNE
stock had been previously titered only in Macaca nem-
estrina, we first assessed its infectiousness in Indian
rhesus macaques. This virus stock (Benveniste et al.,
1990) readily infected two naive rhesus macaques fol-
lowing intrarectal exposure either to 1:5 or to 1:10 dilu-
tions of the SIVMNE stock, and both animals were virus-
solation-positive in four out of five or in six out of six
ttempts, respectively. Therefore, we chose the 1:10 di-
ution for further experimentation. In the experimental
hallenge, virus from this stock infected intrarectally both
he control naive animals 469 and 470, as demonstrated
y the SIVMNE isolation on several occasions from their
PBMC. In contrast, among animals 290, 291, 292, and
295, previously exposed to SIVSME660, and animals 294
and 352, previously exposed to SIV251, animals 290, 291,
94, and 352 apparently resisted infection. Their blood
cored negative for virus isolation in 15 of 15 attempts
ithin 12 months postchallenge (Table 2), and the inabil-
ty to isolate virus was paralleled by the negative finding
f plasma viral RNA by NASBA (Romano et al., 1997). The
atter assay is quantitative for more than 103 viral copies
per ml of plasma. The two virus-isolation-positive ani-
mals, 290 and 294, also became seropositive for SIV
antigen, whereas seroconversion did not occur in the
T
In Vitro Susceptibility of Ma
290 291
Total PBMC 6,500 261; 260a
CD81-depleted PBMC 4,600 662; 520a
% CD81 suppression 0 0; 50a
a 100 TCID50.
b ND 5 not determined.
T
In Vivo Susceptibility of P
Animal
Exposure 1
(vaginal)
Virological
status
Exposure 2a
(intrarectal)
Virol
sta
290 SIVSM 2 SIVMNE 1
291 SIVSM 2 SIVMNE 2
292 SIVSM 2 SIVMNE 2
294 SIV251 2 SIVMNE 1
295 SIVSM 2 SIVMNE 2
352 SIV251 2 SIVMNE 2
469 Naive SIVMNE 1
470 Naive SIVMNE 1
a The animals were exposed to a 1:10 dilution of the SIVMNE viral sto
b ND 5 not done.four animals that were consistently negative for detec-
tion of virus (data not shown).
In the search for additional correlates for resistance to
the SIVMNE challenge, lymphoproliferative responses
were studied as described in Table 1, and a transient
nef-specific proliferative response was found only in an-
imal 291 (Table 3). In addition, attempts to measure CTL
responses in the blood of the six animals, either before
or after SIVMNE challenge, did not reveal significant cyto-
oxic activity (less than 10% killing; data not shown).
nterestingly, all of the four animals that resisted SIVMNE
challenge exposure in vivo demonstrated a decreased
susceptibility to SIVBK28 replication of their PBMC prior to
hallenge (Table 2), and only in one out of four animals
his decreased susceptibility appeared to be dependent
n CD81 T cells (Tables 2 and 3). Considered together,
hese data could suggest that a mucosal preexposure to
ow doses of pathogenic SIV strains may have conferred
esistance to subsequent mucosal challenge with a less-
irulent virus, since both naive controls became infected
nd four out of the six experimental animals did not.
owever, one alternative interpretation of these data is
hat the animals that also resisted the second challenge
ith SIVMNE may be naturally resistant to viral infection as
demonstrated by the decreased susceptibility of their
PBMC to SIVBK28 infection in vitro. Other immune corre-
’ PBMC to SIVBK28 Infection
Animal
292 294 295 352
,625 5,400 1,288 ,Limit; 920a
,000 5,400 1,040 ,Limit; 1,770a
94.8 0 NDb; 94a
sed Macaques to SIVMNE
Immune response
observed
In vitro PBMC
susceptibility
Dependence on
CD81 T cells
2 Yes No
T helper nef response Decreased Partly
2 Decreased Fully
2 Yes No
2 Decreased No
2 Decreased Partly
NDb ND ND
ND ND ND
nveniste et al., 1990).ABLE 2
caques
1
10ABLE 3
reexpo
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394 MARGOLIS ET AL.lates could not be identified because the proliferative
responses in the animals before and after challenge with
SIVMNE were transient and various levels of CD81 T-cell-
associated suppression activity were present in most,
but not all, of the animals that resisted SIVMNE challenge
Tables 2 and 3). Similarly, bulk CTL assays were nega-
ive.
Because the measurement of these immunological
esponses did not reveal any correlation with resistance
o viral infection in vivo, we resorted to exploring a novel
pproach. Blocks of human lymphoid tissue ex vivo sup-
ort infection of diverse HIV strains in the absence of
xogenous stimulation (Glushakova et al., 1997, 1998).
We therefore elected to assess the ex vivo susceptibility
to SIVMNE of the lymph nodes of each animal that resisted
he in vivo challenge with SIVMNE. In parallel, we also
tested the susceptibility to the pathogenic SIV251(32H) viral
tock of the same ex vivo lymph nodes with the intent to
xpose the macaques to this viral stock at a later time.
xperiments were initiated on the ex vivo tissues col-
lected 12 months following SIVMNE challenge after the
virological status of the animals was confirmed. The
kinetics of ex vivo replication of SIVMNE and SIV251(32H) was
first assessed in biopsies of lymph nodes from three
naive animals. The latter virus was chosen because
sufficient amount of in vivo titered viral stock was avail-
able to perform ex vivo and in vivo viral challenge. Figure
1 demonstrates that both viruses replicated efficiently
and that the replication kinetic mirrored that observed in
human tonsils infected ex vivo with different strains of
HIV-1 (Glushakova et al., 1997, 1998). Aliquots from the
SIVMNE and SIV251(32H) viral stocks were then used to infect
x vivo lymph nodes from animals 291, 292, 295, and 352
btained at 12 and 13 months postchallenge, and animal
95 at 15 months postchallenge; their susceptibility to
nfection was assessed by measuring the total amount of
27 gag antigen produced per tissue block over an
8-day period.
Both SIVmac strains readily replicated in the ex vivo
ymph nodes of naive animals to the level of 25–30 ng of
27 (Fig. 1 and Table 4), whereas the replication of the
ame virus in the ex vivo lymph nodes of the experimen-
al animals was at least tenfold less. None of the ex vivo
ymph nodes, except one (axillary lymph node from ani-
al 295), replicated SIVMNE efficiently (p27 gag , 1.18 ng).
Moreover, 1 month later, two additional lymph nodes
from animal 295 also failed to replicate SIVMNE efficiently.
In contrast, SIV251(32H) replicated in nine out of ten lymph
nodes from the experimental animals at levels above 13
ng of p27 gag. On average, SIVMNE replication in lymph
nodes from the challenged animals produced 1.2 6 0.16
ng of p27 gag, whereas SIV251(32H) replication in the same
ymph nodes from the same animals produced 26.8 6 9
g of p27 gag. Thus, viral replication ex vivo appeared in
lymphoid tissue ex vivo to correlate with the resistance of
these animals to SIVMNE infection in vivo. sTo study the molecular basis of this observation, we
analyzed the production of RANTES, MIP1-a, and
IP1-b, the natural ligands for CCR5, since local alter-
tion of their levels could mediate the resistance of
ymph nodes to SIV infection (Benveniste et al., 1990;
annagi et al., 1988; Lehner et al., 1996; Leno et al., 1999;
Wang et al., 1998). Overall, comparable amounts of C-C
chemokines were observed in different ex vivo lymph
nodes from the same animal, whereas variation in che-
mokine production was observed among animals. The
level of variation in the amounts of C-C chemokine pro-
duction did not allow for an evaluation of a possible
correlation between C-C chemokine production and re-
sistance of the ex vivo lymph nodes to SIVMNE (data not
hown).
Since the lymph nodes of the experimental macaques
ppeared to be susceptible ex vivo to SIV251(32H) infection,
e investigated whether this assay reflected the animals’
nfectability in vivo. Therefore, animals 292, 295, and 352,
nd two naive controls (471 and 485) were exposed to 20
ID of SIV251(32H) by the intrarectal route as described
earlier (Benson et al., 1998). Both naive and experimental
macaques became infected by SIV251(32H) as demon-
trated by consecutive successful attempts of virus iso-
ation from PBMC and detection of viral RNA in the
lasma (Fig. 2). The levels of acute and setpoint viremia
n the naive and the previously exposed animals were
FIG. 1. Kinetics of SIVMNE and SIV251(32H) replication in lymph-node
istocultures. Lymph nodes extracted under anesthesia according to
n approved protocol were dissected into 2- to 3-mm blocks and
laced at the air–liquid interface onto the collagen sponge gels (5
locks/gel/3 ml of RPMI1640; media was changed every 3 days) as
escribed earlier (Glushakova et al., 1997, 1998). To infect the tissue
qual doses of SIV in 5–9 ml were applied on top of each tissue block.imilar, and all animals seroconverted to viral antigens
t
l
d
u
a
t
s
v
c
i
a
l
S
e
p
R
t
c
e
m
ND, not determined.
N
a
is used as a positive control (Abimiku et al., 1997).
395LYMPH-NODE SUSCEPTIBILITY TO SIV INFECTIONand experienced a decrease in CD41 T-cell counts
within the 6-month observation period (Fig. 2). Thus,
efficient ex vivo lymph-node infection correlated with the
susceptibility of these macaques to in vivo infection with
SIV251. Furthermore, these data indicate that the resis-
ance of these macaques to SIV infection was not abso-
ute and was likely dependent on the virulence and/or
ose of the viral challenge.
Thus, the doses and virulences of the viral strains
sed in conjunction with innate or, in this case, perhaps
cquired resistance to viral infection greatly influence
he outcome of challenge exposure (Table 5). Ex vivo
usceptibility of lymphoid tissues, including blood, to
iral strains of different virulences may help to define
orrelates of natural or acquired resistance to infection
n the SIV macaque model and may further develop as an
dditional experimental tool to search for immune corre-
ates in studies of HIV-1 vaccine candidates.
MATERIALS AND METHODS
IV infection of simian lymphoid tissue ex vivo
Inguinal, mesenteric, or axillary lymph nodes were
xtracted under anesthesia according to an approved
rotocol and immediately placed in sterile tubes with
PMI1640 medium with antibiotics. Lymph nodes were
ransferred to the laboratory, washed thoroughly with
sma of exposed (top) and control (bottom) animal was measured by
t for mm3 of blood following viral exposure. (C and D) Western blot
represent months following SIV251(32H) challenge. (D) Animal 209 serumTABLE 4
In Vitro Susceptibility of Lymph-Node Histocultures to the SIVMNE
and SIV251(32H) Strains
Animal Location
SIVMNE
a
(ng of p27)
SIV251(32H)
b
(ng of p27c)
13 Months
291 Inguinal NDd 41.9
292 Axillary ND 35.8
295 Axillary 49 65
352 Inguinal ND 63
14 Months
291 Inguinal 1.2 39.1
291 Mesenteric 1.1 ND
292 Inguinal ,0.6 18.0
292 Mesenteric ,0.6 25.2
295 Inguinal 1.7 13.1
295 Mesenteric 1.7 ND
352 Inguinal 1.1 64
352 Mesenteric 1.7 1.8
15 Months
295 Mesenteric ,0.6 30
483 (Control) Inguinal 58 ND
a SIVMNE: the viral stock had a TCID50 of 5 3 10
5 on the A2-clone 5
ell line and was diluted 1:50 to a presumed TCID50 of 104 (Benveniste
t al., 1990).
b SIV251(32H): the viral stock had a TCID50 of 10.
c Total amount of p27 gag antigen produced by five blocks in 3 ml of
edia over an 18-day period.
dFIG. 2. (A) Outcome of SIV251(32H) challenge exposure. Virus load in the pla
ASBA, as previously described (Benson et al., 1998). (B) CD41 T-cell coun
nalyses of the exposed animals’ sera. The numbers on the tops of the panels
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396 MARGOLIS ET AL.medium containing antibiotics/antimicotics, and then
sectioned into 2- to 3-mm blocks. These tissue blocks
were placed on top of collagen sponge gels in culture
medium (RPMI1640 with 15% FCS) at the air–liquid inter-
face and infected as described earlier for human lym-
phoid tissue (Hu, 1994; Kannagi et al., 1988), specifically,
after overnight in culture, tissue blocks were infected
with SIVMNE or SIV251(32H). To normalize the infection dose
for different SIV strains, between 5 and 9 ml of virus-
ontaining media were applied on top of each tissue
lock. Productive SIV infection was assessed by mea-
uring p27 in the culture medium using an SIV p27
ntigen ELISA (Advanced Bioscience Laboratories,
ensington, MD). Specifically, the concentration of p27,
hich accumulated in 3 ml of culture medium bathing a
ponge gel with five tissue blocks during the 3 days
etween the successive medium changes, was used as
measure of virus replication.
mmunological and virological assays
Ficoll-purified PBMC from each animal were stimu-
ated in vitro with the Gag peptide 179–190 (EGCTPYDIN-
ML), used at 5 mM concentration; the peptides from the
SIVMNE Env amino acid sequence 431–445 (NYVCPCHIR-
IINTWH), 108–122 (CITMKCNKSETDKWG), and
06–320 (KYYNLTMKCRRPGNK), used at a 5 mM final
concentration; and the Nef peptides 164–178 (GPRYPK-
TFGWLWKLV), 201–215 (SQWDDPWGEVLVWKF), and
125–140 (EKGGLEGIYYSERRHK), also used at the 5 mM
final concentration.
CD81 suppression
CD81 suppression activity was measured as follows:
Ficoll-purified PBMC from each animal were divided in
two aliquots: one was depleted of CD81 T cells by Ab
a-CD81 conjugated on Dynabead (Dynal, U.K.) and the
T
Primary and Chal
Animal
1994–1995
exposure to
October 1996
Challenge Outcome
290 SIVSME660 SIVMNE Infected
291 SIVSME660 SIVMNE Uninfected
292 SIVSME660 SIVMNE Uninfected
295 SIVSME660 SIVMNE Uninfected
294 SIV251 SIVMNE Infected
352 SIV251 SIVMNE Uninfected
469 Naive SIVMNE Infected
470 Naive SIVMNE Infected
471 Naive
485 Naive
a This animal was euthanized because of postsurgical complicationther was left untreated. Both aliquots were stimulatedwith PHA at 2.5 mg/ml for 48 h, washed, and exposed to
0 TCID50 of BK28 virus stock. The cultures were main-
ained in IL-2 and the amount of p27 in the sample was
ssayed at Day 8. The percentage suppression is de-
ived from the value at Day 8 of p27 gag obtained in the
bsence of CD81 T cells and the level of p27 gag
obtained in the whole PBMC (100%). Virus isolation and
detection of plasma viral RNA by NASBA and Western
blot were performed as previously described (Benson et
al., 1998).
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